Spike (B.1.1.7, Alpha Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)

Products from BPS Bioscience require a minimum order value above 400€

Application: 1. Study the mechanism of viral transduction of SARS-CoV-2 UK variant.
2. Screening for neutralizing antibodies for SARS-CoV-2 Spike (UK variant) and ACE2.

Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. The new B.1.1.7 mutant (UK variant) results in higher transmissibility and infectivity.BPS has developed an off the shelf spike pseudo lentivirus containing the B.1.1.7 variant mutations with a firefly luciferase reporter system. This Lentivirus is ideal for screening and characterizing neutralizing antibodies for the UK variant strain of SARS-CoV-2. The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility.

Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility.

Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS.

Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.

Warnings: Biosafety: None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Biosafety Level: BSL-2

• Artikelnummer: BPS78112-1
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 78112-1
• Verpackungseinheit: 100 µl
• Mengeneinheit: STK